Abstract
Migraine is a paroxysmal disorder with attacks of headache, nausea, vomiting, photo-and phonophobia and malaise. This review summarises new treatment options both for the therapy of the acute attack as well as for migraine prophylaxis. Analgesics like aspirin or nonsteroidal antiinflammatory drugs (NSAIDs) are effective in treating migraine attacks. Few controlled trials were perfomed for the use of ergotamine or dihydroergotamine. These trials indicate inferior efficacy compared to serotonin (5-HT)1B/D-agonists (further on called “triptans”). The triptans (almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan) are highly effective. They improve headache as well as nausea, photo-and phono-phobia. The different triptans have minor differences in efficacy, headache recurrence and adverse effects. The knowledge of their different pharmacological profile allows a more specific treatment of the individual migraine characteristics. Migraine prophylaxis is recommended, when more than 3 attacks occur per month, if attacks do not respond to acute treatment or if side effects of acute treatment are severe. Substances with proven efficacy include the beta-blockers metoprolol and propranolol, the calcium channel blocker flunarizine, several 5-HT antagonists and amitriptyline. Recently antiepileptic drugs (valproic acid, gabapentin, topiramate) were evaluated for the prophylaxis of migraine. The use of botulinum-toxin is under investigation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tfelt-Hansen P (1996) Drug treatment of migraine: acute treatment and migraine prophylaxis. Curr Opin Neurol 9: 211–213
Tfelt-Hansen P (1997) Preliminary analysis of randomized placebo-controlled clinical trials with newer 5-HT1D receptor agonists for the treatment of migraine attacks. In: Olesen J, Tfelt-Hansen P (eds) Headache treatment: trial methodology and new drugs, vol 6. Lippincott-Raven, New York, pp 253–256
Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358: 1668–1675
Tfelt-Hansen P, Block G, Dahlof C, Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PB, for the International Headache Society Clinical Trials Subcommittee (2000) Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20: 765–786
Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine — current understanding and treatment. N Engl J Med 346: 257–270
Tfelt-Hansen P (1998) Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on numbers needed to treat. Cephalalgia 18: 532–538
Pfaffenrath V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38: 184–190
Wilkinson M, Pfaffenrath V, Schoenen J, Diener HC, Steiner T (1995) Migraine and cluster headache — their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia 15: 337–357
Perry CM, Markham A (1998) Sumatriptan. An updated review of its use in migraine. Drugs 55: 889–922
Moore K, Hussey E, Shaw S, Fuseau E, Duquesnoy C, Pakes G (1997) Safety, tolerability and pharmacokinetics of sumatriptan in healthy subjects following ascending intranasal doses and multiple intransal doses. Cephalalgia 17: 541–550
Becker WJ, on behalf of the Study Group (1995) A placebo-controlled, dose-defining study of sumatriptan nasal spray in the acute treatment of migraine. Cephalalgia 15[Suppl 14]: 271–276
Ryan R, Elkind A, Baker CC, Mullican W, DeBussy S, Asgharnejad M (1997) Sumatriptan nasal spray for the acute treatment of migraine. Neurology 49: 1225–1230
Ashford E, Salonen R, Saiers J, Woessner M (1998) Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 18: 273–277
Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M (1998) Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 7: 234–240
Diener HC (2000) Sumatriptan — Therapy. In: Diener HC (ed) Drug treatment of migraine and other headaches. Karger, Basel, pp 93–109
Göbel H, on behalf of the Study Group (1995) A placebo-controlled, dose defining study of sumatriptan suppositories in the acute treatment of migraine. Cephalalgia 15[Suppl 14]: 232
Tepper SJ, Cochran A, Hobbs S, Woessner M, on the behalf of the S2B351 Study Group (1998) Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 52: 31–35
Hämäläinen ML, Hoppu K, Santavuori P (1997) Sumatriptan for migraine attacks in children: A randomized placebo-controlled study. Do children with migraine attacks respond to oral sumatriptan differently from adults? Neurology 48: 1100–1103
Überall MA, Wenzel D (1999) Intranasal sumatriptan for the acute treatment of migraine in children. Neurology 52: 1507–1510
Joffe RT, Sokolov ST (1997) Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr Scand 95: 551–552
Freitag FG, Diamond S, Diamond M, Urban G, Pepper B (1998) Subcutaneous sumatriptan in patients treated with monoamine oxidase inhibitors and other prophylactic agents. Headache Quarterly 9: 165–171
O’Connor P, Gladstone P (1995) Oral sumatriptan-associated transmural myocardial infarction. Neurology 45: 2274–2276
Main ML, Ramaswamy K, Andrews TC (1998) Cardiac arrest and myocardial infarction immediately after sumatriptan injection (letter). Ann Intern Med 128: 874
Ottervanger JP, Paalman HJA, Boxma GL, Strieker BHC (1993) Transmural myocardial infarction with sumatriptan. Lancet 341: 861–862
Mueller L, Gallagher RM, Ciervo CA (1996) Vasospasm-induced myocardial infarction with sumatriptan. Headache 36: 329–331
Ottervanger JP, Strieker BHC (1995) Cardiovascular adverse reactions to sumatriptan — cause for concern? CNS Drugs 3: 90–98
Cavazos JE, Carees JB, Chilukuri VR (1994) Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 343: 1105–1106
Luman W, Gray RS (1993) Adverse reactions associated with sumatriptan. Lancet 341: 1091–1092
Jayamaha JEL, Street MK (1995) Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 21: 82–83
Knudsen JF, Friedman B, Chen M, Goldwasser JE (1998) Ischemic colitis and sumatriptan use. Arch Intern Med 158: 1946–1948
Welch KMA, Mathew NT, Stone P, Rosamond W, Saiers J, Gutterman D (2000) Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 20: 687–695
O’Quinn S, Davis R, Guttermann D, Pait G, Fox A (1999) Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for the acute treatment of migraine. Cephalalgia 19: 223–231
Lewis PJ, Barrington SF, Marsden PK, Maisey MN, Lewis LD (1997) A study of the effects of sumatriptan on myocardial perfusion in healthy male migraineurs using 13NH3 positron emission tomography. Cephalalgia 48: 1542–1550
Shuhaiber S, Pastuszak A, Schick B, Matsui D, Spivey G, Brochu J, Koren G (1998) Pregnancy outcome following first trimester exposure to sumatriptan. Neurology 51: 581–583
Fox AW, Chambers CD, Anderson PO, Diamond ML, Spierings ELH (2002) Evidence-based assessment of pregnancy outcome after sumatriptan exposure. Headache 42: 8–15
Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen J (2000) Pregnancy outcome following prescription for sumatriptan. Headache 40: 20–24
O’Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW (1999) Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 263: 7–12
Goldstein J, Dahlöf CGH, Diener HC, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ, on behalf of the Subcutaneous Alniditan Study G (1996) Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 16: 497–502
Couch JR, Saper J, Meloche JP, for the North American BMS Study Group (1996) Treatment of migraine with BMS 180048: response at 2 hours. Headache 36:523–530
Ryan RE, Elkind A, Goldstein J (1997) Twenty-four-hour effictiveness of BMS 180048 in the acute treatment of migraine headaches. Headache 37: 245–248
John GW, Perez M, Pawels PJ, Le Grand B, Verscheure Y, Colpaert FC (2000) Donitriptan, a unique high efficacy 5-HT1B/1D agonist: key features and acute antimigraine potential. CNS Drug Rev 6: 278–289
Klassen A, Elkind A, Asharnejad M, Webster C, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 37: 630–645
Mathew NT, Asgharnejad M, Peykamian M, Laurenza A, on behalf of the Naratriptan S2WA3001 Study Group (1997) Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 49: 1485–1490
Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Saynor DA, Humphrey PPA (1997) Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 17: 145–152
Gunasekara NS, Wiseman LR (1997) Naratriptan. CNS Drugs 8: 402–408
Goadsby PJ (1998) A triptan too far? J Neurol Neurosurg Psychiatry 64: 143–147
Salonen R (1999) Naratriptan. Int J Clin Pract 53: 552–556
Dahlöf C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J, Boswell D, Fuseau E, Hassani H, Winter P (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 5: 469–477
Heywood J, Bomhof MAM, Pradalier A, Thaventhiran L, Winter P, Hassani H (2000) Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia 20: 470–474
Kempsford RD, Lacey LF, Keene ON (1993) The safety, tolerability and pharmacokinetics of subcutaneous GR 85548, a novel 5-HTl-receptor agonist for the treatment of migraine. Br J Clin Pharmacol 36: 170
Sheftell F, O’Quinn S, Watson C, Pait D, Winter P (2000) Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence. Headache 40: 103–110
Goadsby PJ, Knight YE (1997) Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 17: 153–158
Ferrari MD (1997) 311C90: Increasing the options for the therapy with effective acute antimigraine 5HT1B/D receptor agonists. Neurology 48[Suppl 3]: 21–24
Rapoport AM, Ramadan NM, Adelmann JU, Mathew NT, Elkind AH, Kudrow DB, Earl NL, on behalf of The 017 Clinical Trial Study Group (1997) Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study. Neurology 49: 1210–1218
Dahlöf C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J, Wilkinson M, Sweet RM, Klein KB (1998) Zolmitriptan, a 5-HT1B/D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 5: 535–543
Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC, Sweet R, on behalf of the Study Group (2000) Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 20: 30–38
Solomon GD, Cade RK, Klapper JA, Earl NL, Saper JR, Ramadan NM, on behalf of The 042 Clinical Trial Study Group (1997) Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 49: 1219–1225
Schoenen J, Sawyer J (1997) Zolmitriptan (Zornig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 17[Suppl 18]: 28–40
The International 311C90 Long-Term Study Group (1998) The long-term tolerability and efficacy of oral zolmitriptan (Zornig, 311C90) in the acute treatment of migraine. An international study. Headache 38: 173–183
Becker WJ, Lee D (2001) Zolmitriptan nasal spray is effective, fast-acting and well tolerated during both, short-and long-term treatment. Cephalalgia 21: 271
Dowson AJ, Boes-Hansen S, Farkkila AM (2000) Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine. Eur J Neurol 7[Suppl 3]: 82
Sorensen J, Bergstrom M, Antoni A, Nairn K, Yates R, Kemp J, Dane A (2000) Distribution of HC-zolmitriptan nasal spray assessed by positron emission tomography (PET). Eur J Neurol 7[Suppl 3]: 82
Edmeads JG, Millson DS (1997) Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. Cephalalgia 17: 41–52
Rolan P (1997) Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig (R), 311C90). Cephalalgia 17[Suppl 18]: 21–27
Peck RW, Seaber EJ, Dixon R, Gillotin CG, Weatherley BC, Layton G, Posner J (1997) The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol 44: 595–599
Cutler NR, Claghorn J, Sramek JJ, Block G, Panebianco D, Cheng H, Olah TV, Reines SA (1996) Pilot study of MK-462 in migraine. Cephalalgia 16: 113–116
Visser WH, Terwindt GM, Reines SA, Jiang K, Lines CR, Ferrari MD, for the Dutch/U.S. Rizatriptan Study Group (1997) Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 53: 1132–1137
Teall J, Tuchmann M, Cutler N, Gross M, Willoughby E, Smith B, Jiang K, Reines S, Block G, on behalf of the Rizatriptan 022 Study Group (1998) Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 38: 281–287
Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W, Block GA, Reines SA, Visser WH, on behalf of the Rizatriptan 030 Study Group (1998) Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 38: 748–755
Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block G, Lines C, and the Rizatriptan Protocol 046 Study Group (1998) Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine. Headache 38: 737–747
Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP, McHugh W, Feighner J, Silberstein S, Reines SA, and the Rizatriptan Multiple Attack Study Group (1998) A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 51: 773–781
Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K, and the Rizatriptan-Zolmitriptan Study Group (2000) Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 20: 455–461
Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K (1999) Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 42: 173–179
Goadsby PJ (2000) Rizatriptan in acute treatment of migraine: update on new comparative data. Cephalalgia 20[Suppl 1]: 10–15
Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA, Visser WH, and the Rizatriptan Wafer Protocol 049 Study Group (1999) Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 19: 525–530
Adelman JU, Mannix LK, Seggern von RL (2000) Rizatriptan tablet versus wafer: patient preference. Headache 40: 371–372
Klapper JA, O’Connor S (2000) Rizatriptan wafer-sublingual vs. placebo at the onset of acute migraine. Cephalalgia 20: 585–587
Diener HC, McHarg A (2000) Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. Int J Clin Pract 54: 670–674
Färkkilä M, Diener HC, Dahlöf C, Steiner TJ, on behalf of the Eletriptan Steering Committee (1996) A dose-finding study of eletriptan (5–30 mg) for the acute treatment of migraine. Cephalalgia 16: 387
Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC, Poole PH, for the Eletriptan Steering Committee (2000) Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 54: 156–163
Steiner TJ, on behalf of the Eletriptan Steering Committee (1998) The efficacy, saftey and tolerability of oral eletriptan (40 mg and 80 mg) for the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group clinical trial. Migraine Trust, London
Diener HC, Reches A, Pascual J, Jansen J-P, Pitei D, Steiner T, on behalf of the Eletriptan and Cafergot Comparative Study Group (2002) Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 47: 99–107
Cabarrocas X, Zayas JM, on behalf of the Almotriptan Oral Study Group (1998) Efficacy data on oral almotriptan, a novel 5-HT1B/D agonist. Headache 38: 377
Pascual J (2000) Therapy with other triptans: almotriptan. In: Diener HC (ed) Drug treatment of migraine and other headaches. Karger, Basel, pp 197–205
Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, Ferrer P, Luria X, Segarra R, Zayas JM (2000) Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 20: 588–596
Cabarrocas X, Zayas JM, Suris M, on behalf of the Almotriptan Oral Study Group (1998) Equivalent efficacy of oral almotriptan, a new 5-HT1B/D agonist, compared with sumatriptan 100 mg. Headache 38: 377–378
Spierings E, Gomez-Mancilla B, Grosz D, Rowland C, Whaley F, Jirgens K (2001) Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 58: 944–950
Mathew NT, for the Oral Almotriptan Study Group (2002) A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine. Headache 42: 32–40
Cabarrocas X, Esbri R, Peris F, Ferrer P (2001) Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 41: 57–62
Brown AM, Ho M, Thomas DR, Parson AA (1998) Comparison of functional effects of frovatriptan, sumatriptan and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors. Headache 38: 376
Goldstein J, Elkind A, Keywood C, Klapper J, Ryan R (1998) A low dose range-finding study of frovatriptan: a potent selective 5-HT1B/D agonist for the acute treatment of migraine. Headache 38: 382–383
Goldstein J, Keywood C, 251/96/14 Study Group (2002) Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache 42: 41–48
The International Headache Society Committee on Clinical Trials in Migraine (1991) Guidelines for controlled trials of drugs in migraine 1st edn. Cephalalgia 11: 1–12
Pilgrim AJ (1991) Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 31: 295–299
Tfelt-Hansen P (1998) Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 18: 532–538
Ferrari MD (1999) The war of the triptans. Teaching course, Syllabus, EFNS, Lisbon
Stark S, Spierings ELH, McNiel S, Putnam GP, Bolden-Watson CP, O’Quinn S (2000) Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 40: 513–520
Visser WH, Jaspers N, de Vriend RHM, Ferrari MD (1996) Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 16: 264–269
McDavis HL, Hutchison J, Frovatriptan Phase III Investigators (1999) Frovatriptan — a review of overall clinical efficacy. Cephalalgia 19: 363–364
Diener HC, Tfelt-Hansen P (1993) Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The headaches. Raven Press, New York, pp 721–727
Kaube H, May A, Diener HC, Pfaffenrath V (1994) Sumatriptan misuse in daily chronic headache. BMJ 308: 1573
Gaist D, Hallas J, Sindrup SH, Gram LF (1996) Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 3: 161–165
Gaist D, Tsiropoulus I, Sindrup SH, Hallas J, Rasmussen BK, Kragstrup J (1998) Inappropriate use of sumatriptan: population based register and interview study. Br J Med 316: 1352–1353
Gaist D (1999) Use and overuse of sumatriptan. Pharmaco-epidemiological studies based on prescription register and interview data. Cephalalgia 19: 735–761
Katsarava Z, Fritsche G, Diener HC, Limmroth V (2000) Drug-induced headache (DIH) following the use of different triptans. Cephalalgia 20: 293 [abstract]
Limmroth V, Kazarawa S, Fritsche G, Diener HC (1999) Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 353: 378
MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98: 25–30
MassenVanDenBrink A, Bax WA, Ramrattan NN, Ferrari MD, Saxena PR (1999). Human isolated coronary artery contraction to sumatriptan: a post hoc analysis. Cephalagia 19: 651–654
Cady RK, Lipton RB, Hall C, Stewart WF, O’Quinn S, Gutterman D (2001) Treatment of mild headache in disabled migraine sufferers: results of the Spectrum study. Headache 40: 792–797
Diener HC, for the RPR100893–201 Migraine Study Group (1995) Substance P antagonist RPR100893–201 is not effective in human migraine attacks. 6th International Headache Research Seminar, Copenhagen, pp 245–371
Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein ST, Mathew NT (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: crossover study. Cephalalgia 17: 785–790
May A, Gijsman HJ, Wallnöfer A, Jones R, Diener HC, Ferrari MD (1996) Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 67: 375–378
Lassen LH, Ashina M, Christiansen I, Ulrich V, Gròver R, Donaldson J, Olesen J (1998) Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 18: 27–32
Ramadan N, Sang C, Chappell A, Vandenhende F, Johnson K, Phebus L, Bleakman D, Ornstein P, Arnold B, Freitag F, Smith T, Silberstein S, Tepper S (2001) IV LY293558, an AMPA/KA receptor antagonist, is effective in migraine. Cephalalgia 21: 267
Phebus LA, Johnson KW, Zgombick JL, et al. (1997) Characterization of LY334370 as a pharmacological tool to study 5HT1F receptors binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61: 2117–2126
Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD (2001) Selective serotonine IF (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358: 1230–1234
Lipton RB, Stewart WF, Ryan RE, Saper J, Silberstein S, Sheftell F (1998) Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain ¡ª Three double-blind, randomized, placebo-controlled trials. Arch Neurol 55: 210–217
Myllylä VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J, Vapaatalo H, Eskerod O (1998) Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, prallel-group study. Headache 38: 201–207
Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclo-pramide compared with oral sumatriptan for migraine. Lancet 346: 923–926
Codispoti JR, Prior M J, Fu M, Harte CM, Nelson EB (2001) Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 41: 665–679
Dahlöf C, Björkman R (1993) Diclofenac-K (50 and 100mg) and placebo in the acute treatment of migraine. Cephalalgia 13: 117–123
Karachalios GN, Fotiadou A, Chrisikos N, Karabetsos A, Kehagioglou K (1992) Treatment of acute migraine attack with diclofenac sodium: a double-blind study. Headache 32: 98–100
The Diclofenac-K/Sumatriptan Migraine Study Group (1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia 19: 232–240
de Craen AJM, Tijssen JGP, de Gans J, Kleijnen J (2000) Placebo effect in the acute treatment of migraine: subcutaneous placebos are better than oral placebos. J Neurol 247: 183–188
McQuay H, Carroll D, Moore A (1995) Variation in the placebo effect in randomised controlled trials of analgesics: all is as blind as it seems. Pain 64: 331–335
Migraine-Nimodipine European Study Group M (1989) European multicenter trial of nimodipine in the prophylaxis of common migraine (migraine without aura). Headache 29: 633–638
Migraine-Nimodipine European Study Group M (1989) European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Headache 29: 639–642
Couch JR (1987) Placebo effect and clinical trials in migraine therapy. Neuro-epidemiology 6: 178–185
Rabkin R, Stables DP, Levin NW, Suzman MM (1966) The prophylactic value of propranolol in angina pectoris. Am J Cardiol 18: 370–383
Holroyd KA, Penzien DB, Cordingley GE (1991) Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31: 333–340
Kangasniemi P, Hedman C (1984) Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 4: 91–96
Ljung O (1980) Treatment of migraine with metoprolol. N Engl J Med 303(3): 664–668
Steiner TJ, Joseph R, Hedman C, Clifford Rose F (1988) Metoprolol in the prophylaxis of migraine: parallel group comparison with placebo and dose-ranging follow-up. Headache 28: 15–23
Olsson JE, Behring HC, Forssman B, Hedman C, Hedman G, Johansson F, Kinnman J, Palhagen SE, Samuelsson M, Strandman E (1984) Metoprolol and propranolol in migraine prophylaxis: a double-blind multicenter study. Acta Neurol Scand 70: 160–168
Sorensen PS, and the Danish Migraine Study Group (1989) Prophylactic effect of flunarizine versus metoprolol in migraine. Cephalalgia 9: 355–356
Sorensen PS, Larsen BH, Rasmussen MJK, Kinge E, Iversen H, Alslev T, Nohr P, Pedersen KK, Schroder P, Lademann A, Olesen J (1991) Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 31: 650–657
Vilming S, Standnes B, Hedman C (1985) Metoprolol and pizotifen in the prophylactic treatment of classical and common migraine. A double-blind investigation. Cephalalgia 5: 17–23
Wörz R, Reinhardt-Benmalek B, Grotemeyer KH, Foh M (1991) Bisoprolol and metoprolol in the prophylactic treatment of migraine with and without aura — a randomized double-blind cross-over multicenter study. Cephalalgia 11 [Suppl 11]: 152–153
Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS (1992) Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci 19: 340–345
Holroyd KA, Penzien DB, Rokicki LA, Cordingley GE (1992) Flunarizine vs propranolol: a meta-analysis of clinical trials. Headache 32: 256
Ludin H-P (1989) Flunarizine and propranolol in the treatment of migraine. Headache 29: 218–223
Lucking CH, Oestreich W, Schmidt R, Soyka D (1988) Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 8: 21–26
Shimell CJ, Fritz VU, Levien SL (1990) A comparative trial of flunarizine and propranolol in the prevention of migraine. S Afr Med J 77: 75–78
Forssman B, Lindblad CJ, Zbornikova V (1983) Atenolol for migraine prophylaxis. Headache 23: 188–190
Stensrud P, Sjaastad O (1980) Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Headache 20: 204–207
Briggs RS, Millac PA (1979) Timolol in migraine prophylaxis. Headache 19: 379–381
Stellar S, Ahrens S, Meibohm AR, Reines AS (1984) Migraine prevention with timolol. A double-blind crossover study. Jama 252: 2576–2580
Tfelt-Hansen P, Standnes B, Kangasniemi P, Hakkarainen H, Olesen J (1984) Timolol vs. propranolol vs. placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 69: 1–8
Freitag FG, Diamond S (1984) Nadolol and placebo comparison study in the prophylactic treatment of migraine. J Am Osteopath Assoc 84: 343–347
van de Ven LLM, Franke CL, Koehler PJ, on Behalf of the Investigators (1997) Prophylactic treatment of migraine with bisoprolol: a placebo-controlled study. Cephalalgia 17: 596–599
Wörz R, Reinhard-Benmalek B, Foeh M, Grotemeyer KH, Scharafinski HW (1992) Migraine prophylaxis with bisoprolol. Headache Quarterly 3: 64–72
Olesen J, Tfelt-Hansen P, Welch KMA (eds) (1998) The headaches, 2nd ed. Raven Press, New York
Diener HC (2000) Flunarizine for migraine prophylaxis. In: Diener HC (ed) Drug treatment of migraine and other headaches. Karger, Basel, pp 269–278
Markley HG, Cheronis CD, Piepho RW (1984) Verapamil in prophylactic therapy of migraine. Neurology 34: 973–976
Solomon CGD, Steel MJG, Spaccavento CLJ (1983) Verapamil prophylaxis of migraine. Jama 250: 2500–2502
Scholz E, Gerber WD, Diener HC, Langohr HD, Reinecke M (1987) Dihydroergotamine versus flunarizine versus nifedipine versus metoprolol versus propranolol in migraine prophylaxis. A comparative study based on time series analysis. In: Clifford Rose F (ed) Advances in headache research. John Libbey & Co, London, pp 135–145
Albers GW, Simon LT, Hamik A, Peroutka SJ (1989) Nifedipine versus propranolol for the initial prophylaxis of migraine. Headache 29: 214–217
Diener H, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S, on behalf of the Study Group (2001) Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. Cephalalgia 21: 66–70
Neumann M, Demarez JP, Harmey JL, Le Bastard B, Cauquil J (1986) Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharm Res 6: 11–13
Grotemeyer K-H, Schlake H-P, Husstedt IW (1989) Etilefrine pivalate vs. dihydroergotamin and flunarizin in prophylactic treatment of migraine in patients with low blood pressure ¡ª a randomized double-blind-study. Cephalalgia 9: 433–434
Silberstein SD (1998) Methysergide. Cephalalgia 18: 421–435
Buring JE, Peto R, Hennekens CH (1990) Low-dose aspirin for migraine prophylaxis. JAMA 264: 1711–1713
Grotemeyer K, Scharafinski H, Schlake H, Husstedt IW (1990) Acetylsalicylic acid vs metoprolol in migraine prophylaxis ¡ª a double blind cross-over study. Headache 30: 639–641
Diener HC, Härtung E, Chrubasik J, Evers S, Schoenen J, Gendolla AGL, Hauke W, for the Study Group (2001) A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. Cephalalgia 21: 140–144
Bensenor IM, Cook NR, Lee I-M, Chown MJ, Hennekens CH, Buring JE (2001) Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 21: 175–183
Ziegler DK, Ellis DJ (1985) Naproxen in prophylaxis of migraine. Arch Neurol 42: 582–584
Behan PO, Connelly K (1986) Prophylaxis of migraine: a comparison between naproxen sodium and pizotifen. Headache 26: 237–239
Bellavance AJ, Meloche JP (1990) Comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 30: 710–715
Sargent J, Solbach P, Damasio H, Baumel B, Corbett J, Eisner L, Jessen B, Kudrow L, Mathew N, Medina J, Saper J, Vijayan N, Watson C, Alger J (1985) A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache 25: 320–324
Sanees G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G (1990) Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 30: 705–709
Diamond S, Freitag FG, Gallagher RM, Feinberg DT (1990) Ketoprofen in the prophylaxis of migraine. Headache Quarterly 1: 75–77
Johnson RH, Hornabrook RW, Lambie DG (1986) Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 73: 490–492
Mikkelsen B, Pedersen KK, Christiansen LV (1986) Prophylactic treatment of migraine with tolfenamic acid, propranolol and placebo. Acta Neurol Scand 73: 423–427
Couch JR, Hassanein RS (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36: 695–699
Ziegler DK, Hurwitz A, Hassanein RS (1987) Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 44: 486–489
Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J (1993) Propranolol and amitriptyline in prophylaxis of migraine. Arch Neurol 50: 825–830
Bussone G, Cerbo R, Martucci N, Micieli G, Zanferrari C, Grazzi L, Fabbrini G, Cavallini A, Granella F, Ambrosoli L, Mailland F, Poli A, Manzoni G (1999) Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache 39: 426–431
Peikert A, Wilimzig C, Köhne-Volland R (1996) Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 16: 257–263
Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M (1996) Magnesium in the prophylaxis of migraine ¡ª a double-blind, placebo-controlled study. Cephalalgia 16: 436–440
Schoenen J, Lenaerts M, Bastings E (1994) High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 14: 328–330
Schoenen J, Jacquy J, Lenaerts M (1997) High-dose power riboflavin as a novel prophylactic antimigraine therapy: results from a double-blind, randomized, placebo-controlled trial. Cephalalgia 17: 244
Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX Migraine Clinical Research Group (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40: 445–450
Hering R, Kurzitzky A (1992) Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 12: 81–84
Jensen R, Brinck T, Olesen J (1994) Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 44: 647–651
Kaniecki RG (1997) A comparision of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 54: 1141–1145
Klapper J, on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 17: 103–108
Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL (1995) Migraine prophylaxis with divalproex. Arch Neurol 52: 281–286
Steiner TJ, Findley LJ, Yuen AWC (1997) Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 17: 109–112
Lampi C, Buzath A, Klinger D, Neumann K (1999) Lamotrigine in the prophylactic treatment of migraine aura — a pilot study. Cephalalgia 19: 58–63
Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S (2001) Efficacy of gabapentin in migraine prophylaxis. Headache 41:119–128
Potter DL, Hart DE, Calder CS, Storey JR (2000) A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology 54[Suppl 3]: A15
Shuaib A, Ahmed F, Muratoglu M, Kochanski P (1999) Topiramate in migraine prophylaxis: a pilot study. Cephalalgia 19(4): 379–380
Shuaib A (2000) Efficacy of topiramate in prophylaxis of frequent severe migraines or chornic daily headaches: experience with 68 patients over 18 months. Cephalalgia 20: 423
Storey JR, Calder CS, Hart DE, Potter DL (2001) Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 41: 968–975
Newman LC, Lipton RB, Lay CL, Solomon S (1998) A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 51: 307–309
Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Pait Putnam DG, Watson C, Jöbsis M, Batenhorst A, O’Quinn S (2001) Naratriptan as short-term prophylaxis in menstrually associated migraine: a randomised, double-blind, placebo-controlled study. Headache 41: 248–256
Pradalier A, Vincent D, Beaulieu PH, Baudesson G, Launay JM (1994) Correlation between between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Clifford-Rose F (ed) New advances in headache research. Smith-Gordon, London, pp 129–132
Hershey AD, Powers SW, Bentti AL, Grauw de TJ (2000) Effectiveness of amitrip-tyline in the prophylactic management of childhood headaches. Headache 40: 539–549
Lanzi G, Balottin U, Zambrino CA, Cernibori A, Del Bene E, Gallai V, Guidetti V, Sorge F (1996) Guidelines and recommendations for the treatment of migraine in pediatric and adolescent patients. Funct Neurol 11: 269–275
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag/Wien
About this paper
Cite this paper
Diener, HC. (2003). Pharmacological Approaches to Migraine. In: Neuropsychopharmacology. Journal of Neural Transmission. Supplementa, vol 64. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6020-6_3
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6020-6_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83903-4
Online ISBN: 978-3-7091-6020-6
eBook Packages: Springer Book Archive